Differential Modulation of Baroreceptor Sensitivity by Long-term Antihypertensive Treatment

Author:

Ichikawa Masashi1,Suzuki Hiromichi1,Kumagai Kazuhiro1,Kumagai Hiroo1,Ryuzaki Munekazu1,Nishizawa Masahiko1,Saruta Takao1

Affiliation:

1. From the Department of Internal Medicine, Keio University, School of Medicine, Tokyo, Japan.

Abstract

Abstract We investigated the effects of long-term oral treatment with four different classes of antihypertensive drugs (a thiazide diuretic [trichlormethiazide, 10 mg/kg per day]; a β-blocker [atenolol, 90 mg/kg per day]; a calcium channel antagonist [nicardipine, 150 mg/kg per day]; and an angiotensin-converting enzyme inhibitor [enalapril maleate, 10 mg/kg per day]) on aortic baroreceptor activity in spontaneously hypertensive rats with chronic hypertension (36 weeks of age). Treatment with each of the four drugs, given from 10 to 36 weeks of age, similarly decreased arterial pressure (171±2 to 144±1 mm Hg, P <.01) and similarly decreased the threshold pressure for baroreceptors (116±3 to 103±1 mm Hg, P <.05). The four antihypertensive drugs also potentiated the maximal gain of the pressure-activity relation in these rats (untreated, 1.08±0.05% maximum/mm Hg); however, nicardipine and enalapril (1.77±0.04% and 1.70±0.06% maximum/mm Hg, respectively) augmented the maximal gain to a greater extent (P <.05 to .01) than did trichlormethiazide or atenolol (1.49±0.05% and 1.42±0.02% maximum/mm Hg, respectively). When the initiation of treatment was delayed to 28 weeks of age, no differences were found in the effects on either threshold pressure (104±1 mm Hg) or maximal gain (1.36±0.03% maximum/mm Hg) for all four drugs. These findings suggest that in the treatment of chronic hypertension (1) baroreceptor resetting to a lower pressure level is similarly induced with the four drugs, and (2) baroreceptor sensitivity is augmented more by early and long-term treatment with calcium channel antagonists or angiotensin-converting enzyme inhibitors than by diuretics or β-blockers.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3